New Releases from NCBI BookshelfGefapixant for treating refractory or unexplained chronic cough (terminated appraisal).Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal).
Post Content
Uncategorized
Uncategorized
New Releases from NCBI BookshelfPsychological and psychosocial treatment of harmful gambling: Gambling-related harms: identification, assessment and management: Evidence review F.Psychological and psychosocial treatment of harmful gambling: Gambling-related harms: identification, assessment and management: Evidence review F.
Post Content
Uncategorized
New Releases from NCBI BookshelfTrastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal).Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal).
Post Content
Uncategorized
New Releases from NCBI BookshelfEvidence reviews for increasing uptake of weight management services in children, young people and adults: Overweight and obesity management: preventing, assessing and managing overweight and obesity: Evidence review E.Evidence reviews for increasing uptake of weight management services in children, young people and adults: Overweight and obesity management: preventing, assessing and managing overweight and obesity: Evidence review E.
Post Content
Uncategorized
New Releases from NCBI BookshelfBenefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.
Chronic kidney disease affects around 10% of the global population and is associated with significant risk of progression to end-stage